Spinal Cord Injury. Clinical Trial
Official title:
Evaluation of Conventional and Innovative Standing Frame for the Treatment of Osteoporosis After Spinal Cord Injury
Verified date | September 2005 |
Source | Toronto Rehabilitation Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
The purpose of this study is to find out if standing and/or standing with vibration works for the treatment of osteoporosis for people with a spinal cord injury.
Status | Completed |
Enrollment | 60 |
Est. completion date | July 2001 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Traumatic spinal cord injury of greater than 12 months. - Osteopenia or osteoporosis of the hip. Exclusion Criteria: - Pregnant or lactating females. - Nonunion lower extremity fracture within the last 6 months. - Bilateral hip or knee flexion contractures. - Bilateral lower extremity total hip or knee replacement. - Heterotopic ossification of the hip or knee. - Concurrent treatment with a bisphosphonate. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Toronto Rehab, Lyndhurst Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Toronto Rehabilitation Institute | Ontario Neurotrauma Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in bone mineral density from baseline of the hip, distal femur and proximal tibia at 6-months and 12-months. | |||
Secondary | Spasticity (modified Ashworth). | |||
Secondary | Quality of life. | |||
Secondary | Frequency and severity of adverse events. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01833975 -
Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury
|
Phase 1/Phase 2 |